Coulson A S, Summers L J, Lindahl-Kiessling K, Tucker D, Hellmann K
Clin Exp Immunol. 1970 Aug;7(2):241-7.
The soluble thalidomide derivatives, 1-(morpholinomethyl)-4-phthalimido-piperidindione-2,6 (CG603) and its isomer 1-(morpholinomethyl)-3-phthalimido-piperidindione-2,6 (CG601) have been found to inhibit the production of transformed cells in 90-hr mixed lymphocyte cultures from two unrelated human donors. In 72-hr phytohaemagglutinin cultures however, the incorporation of thymidine into the acid insoluble fraction was not inhibited by the same concentration of drugs. Since the initial event in the mixed lymphocyte reaction is considered to be immunological whereas the response to phytohaemagglutinin is not, one possible explanation is that the compounds act by blocking a step in the lymphocyte stimulation pathway between the reception of the antigen, and the site where the phytohaemagglutinin bypass is effective.
已发现可溶性沙利度胺衍生物1-(吗啉甲基)-4-邻苯二甲酰亚氨基哌啶二酮-2,6(CG603)及其异构体1-(吗啉甲基)-3-邻苯二甲酰亚氨基哌啶二酮-2,6(CG601)可抑制来自两名无关人类供体的90小时混合淋巴细胞培养物中转化细胞的产生。然而,在72小时的植物血凝素培养物中,相同浓度的药物并未抑制胸腺嘧啶核苷掺入酸不溶性部分。由于混合淋巴细胞反应中的初始事件被认为是免疫性的,而对植物血凝素的反应则不是,一种可能的解释是这些化合物通过阻断淋巴细胞刺激途径中抗原接收与植物血凝素旁路有效位点之间的一个步骤来发挥作用。